Chiloiro Sabrina, Appetecchia Marialuisa, Bianchi Antonio, Costa Denise, De Acetis Christine, Gargiulo Patrizia, Giampietro Antonella, Isidori Andrea M, Jaffrain-Rea Marie-Lise, Passeri Marina, Pigliaru Francesca, Poggi Maurizio, De Marinis Laura
Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
Division of Endocrinology, University Hospital Fondazione Policlinico Gemelli, IRCCS, Rome, Italy.
Drugs Context. 2024 May 20;13. doi: 10.7573/dic.2024-1-2. eCollection 2024.
Pasireotide-LAR is recommended as a second-line treatment for patients with acromegaly. Although the effects of pasireotide-LAR have been well characterized in clinical studies, real-practice evidence is scant, especially in the long term and within the individualization of therapy in patients with comorbidities. To provide additional insight on the individualized approach to acromegaly management, six clinical cases of complex acromegaly treated with pasireotide-LAR for more than 5 years were reported. Pasireotide-LAR allowed the normalization of insulin-like growth factor 1 (IGF1) values in all patients and reduced tumour residue volume where present. A good safety profile and long-term tolerability were also reported.
帕西瑞肽长效注射剂被推荐作为肢端肥大症患者的二线治疗药物。尽管帕西瑞肽长效注射剂的疗效在临床研究中已有充分描述，但实际应用中的证据却很少，尤其是在长期治疗以及合并症患者治疗个体化方面。为了深入了解肢端肥大症管理的个体化方法，本文报告了6例接受帕西瑞肽长效注射剂治疗5年以上的复杂肢端肥大症临床病例。帕西瑞肽长效注射剂使所有患者的胰岛素样生长因子1（IGF1）值恢复正常，并减少了存在的肿瘤残余体积。同时也报告了良好的安全性和长期耐受性。
